Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced results from its Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA